ENLIVEX THERAPEUTICS LTD (ENLV)
IL0011319527 - Common Stock
ENLV gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 612 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ENLV as it has an excellent financial health rating, but there are worries on the profitability. ENLV is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
ENLV had negative earnings in the past year.
In the past year ENLV has reported a negative cash flow from operations.
In the past 5 years ENLV always reported negative net income.
ENLV had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The profitability ratios for ENLV are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ENLV so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, ENLV has more shares outstanding
The number of shares outstanding for ENLV has been increased compared to 5 years ago.
There is no outstanding debt for ENLV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ENLV has an Altman-Z score of -1.01. This is a bad value and indicates that ENLV is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.01, ENLV is in line with its industry, outperforming 55.30% of the companies in the same industry.
There is no outstanding debt for ENLV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.01 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 6.89 indicates that ENLV has no problem at all paying its short term obligations.
With a decent Current ratio value of 6.89, ENLV is doing good in the industry, outperforming 61.76% of the companies in the same industry.
ENLV has a Quick Ratio of 6.89. This indicates that ENLV is financially healthy and has no problem in meeting its short term obligations.
ENLV has a Quick ratio of 6.89. This is in the better half of the industry: ENLV outperforms 61.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.89 | ||
| Quick Ratio | 6.89 |
3. Growth
3.1 Past
ENLV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -53.42%.
EPS 1Y-53.42%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q13.33%
Revenue growth 1YN/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
ENLV is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.34% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1.4%
EPS Next 2Y4.34%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ENLV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ENLV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.34%
EPS Next 3YN/A
5. Dividend
5.1 Amount
ENLV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ENLIVEX THERAPEUTICS LTD
NASDAQ:ENLV (9/28/2023, 9:16:59 AM)
1.5701
-0.03 (-1.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2023-07-31/bmo
Earnings (Next)N/A N/A
Inst Owners1.71%
Inst Owner Change-0.22%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap29.19M
Analysts82.86
Price Target15.3 (874.46%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.9%
Min EPS beat(2)-0.62%
Max EPS beat(2)4.41%
EPS beat(4)1
Avg EPS beat(4)-4.66%
Min EPS beat(4)-17.65%
Max EPS beat(4)4.41%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.58 | ||
| P/tB | 0.58 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.63
EYN/A
EPS(NY)-1.54
Fwd EYN/A
FCF(TTM)-1.82
FCFYN/A
OCF(TTM)-1.42
OCFYN/A
SpSN/A
BVpS2.72
TBVpS2.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 918.8% | ||
| Cap/Sales | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.89 | ||
| Quick Ratio | 6.89 | ||
| Altman-Z | -1.01 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)564.88%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y-53.42%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q13.33%
EPS Next Y-1.4%
EPS Next 2Y4.34%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue growth 1YN/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-121.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-87.32%
OCF growth 3YN/A
OCF growth 5YN/A